A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer

Lung Cancer

Volumn 38, Issue 1, 2002, Pages 73-77

  Bhatia, Sumeet ^a,b   Hanna, Nasser ^a,b   Ansari, Rafat ^b,c   Pletcher, William ^b,d   Einhorn, Lawrence ^a,b   Ng, Elizabeth ^a,b   Sandler, Alan ^e  

^a INDIANA UNIVERSITY   (United States)

^b Hoosier Oncology Group   (United States)

^c Northern Indiana Cancer Research Consortium   (United States)

^d Elkhart Clinic   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gemcitabine; Non small cell lung cancer; Paclitaxel

Indexed keywords

GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG RESPONSE; HUMAN; HYPOXIA; LUNG NON SMALL CELL CANCER; MORTALITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; STANDARD; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PACLITAXEL; PNEUMONIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036806170     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00145-9     Document Type: Article

References (17)

1. Greenlee R., Murray T., Bolden S. Cancer statistics. CA Cancer J. Clin. 50:2000;7-33.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 311:1995;899-909.
3. Sandler A.B., Nemunaitis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 18:2000;122-130.
4. Schiller J.H., Harrington D., Belani C., et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 346:2002;92-98.
5. Abratt R.P., Bezwoda W.R., Falkson G., et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 12:1994;1535-1540.
6. Murphy W.K., Fossella F.V., Winn R.J., et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 85:1993;384-388.
7. Kroep J., Tolis C., Voorn D. Paclitaxel and gemcitabine cell cycle interactions in non small cell lung cancer lines. Proc. Am. Assoc. Ca. Res. 40:1999;678. abstract.
8. Kroep J.R., Giaccone G., Voorn D.A., et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J. Clin. Oncol. 17:1999;2190-2197.
9. Einhorn L., Raghavan D., Kindler H., et al. A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors. Proc. Am. Soc. Clin. Oncol. 17:1998;207a. abstract.
10. Oken M.M., Creech R.H., Tormey D.C. Toxicity and response criteria for the Eastern Co-operative Oncology Group. Am. J. Clin. Oncol. 5:1982;649-655.
11. Douillard J.Y., Lerouge D., Monnier A., et al. Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study. Br. J. Cancer. 84:2001;1179-1184.
12. Kosmidis P. Interim results of a phase III trial: paclitaxel/carboplatin vs. paclitaxel/gemcitabine in advanced non-small-cell lung cancer. Oncology (Huntington). 14:2000;41-48.
13. Isla D., Rosell R., Sanchez J.J., et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 19:2001;1071-1077.
14. Hainsworth J.D., Burris H.A. III, Greco F.A. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin. Oncol. 28:2001;21-25.
15. Van Meerbeeck J.P., Smit E.F., Lianes P., et al. A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;1228. abstract.
16. Thomas M., Rube C., Semik M., et al. Trimodality therapy in stage III non-small cell lung cancer: prediction of recurrence by assessment of p185neu. Eur. Resp. J. 13:1999;424-429.
17. Roychowdhury D., Smith C., Peterson P. Infrequency of serious pulmonary toxicity with gemzar: analysis of a large database. Proc. Am. Soc. Clin. Oncol. 19:2000;762. abstract.